<DOC>
	<DOCNO>NCT02144272</DOCNO>
	<brief_summary>The main purpose study learn safety LY3114062 find well tolerated participant inflammatory arthritis . The study also investigate body process drug drug affect inflammatory arthritis . The study expect last 3 month .</brief_summary>
	<brief_title>Safety Study Evaluate LY3114062 Participants With Inflammatory Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<criteria>Signs symptom inflammatory arthritis duration least 8 week screen . Presence least 3 66 swollen joint screen baseline , determine swollen joint count assessment form . Synthetic diseasemodifying antirheumatic drug DMARD use follow : ANY treatment tofacitinib within 28 day prior baseline plan treatment tofacitinib study ; Treatment synthetic DMARDs ( eg , hydroxychloroquine , methothrexate , leflunomide , sulfasalazine , gold salt ) unstable dose within 28 day prior baseline dose drug plan change study . Previous treatment market biologic DMARDs follow : Etanercept , adalimumab , anakinra &lt; 4 week prior baseline ; Infliximab , certolizumab pegol , golimumab , abatacept , tocilizumab &lt; 8 week prior baseline ; Rituximab &lt; 12 month prior baseline Note : Other biologic agent indication inflammatory arthritis may allow discussion sponsor Treatment &gt; 10 mg/day , unstable dose , oral prednisone equivalent within 28 day prior baseline . Confirmed suspect septic arthritis , crystal arthropathy , systemic lupus erythematosus , reactive arthritis , certain rheumatic condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Antibody</keyword>
	<keyword>Tumor Necrosis Factor alpha</keyword>
	<keyword>Interleukin-17</keyword>
</DOC>